hit counter
Apollo Endosurgery, Inc. (APEN) Stock News Sentiment & Price - Sentifly
APEN - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Apollo Endosurgery, Inc. (APEN)

USA
Medical Appliances & Equipment
NASDAQ
APEN Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
APEN Latest news
Zacks Investment Research
Positive
Apollo Endosurgery, Inc. (APEN) Moves to Buy: Rationale Behind the Upgrade
2021-11-04 13:45

Apollo Endosurgery, Inc. (APEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research
Positive
How Much Upside is Left in Apollo Endosurgery, Inc. (APEN)? Wall Street Analysts Think 35%
2021-11-04 10:42

The consensus price target hints at a 35.4% upside potential for Apollo Endosurgery, Inc. (APEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Seeking Alpha
Neutral
Apollo Endosurgery, Inc. (APEN) CEO Charles McKhann on Q3 2021 Results - Earnings Call Transcript
2021-11-01 21:55

Apollo Endosurgery, Inc. (APEN) CEO Charles McKhann on Q3 2021 Results - Earnings Call Transcript

Benzinga
Positive
Recap: Apollo Endosurgery Q3 Earnings
2021-11-01 16:59

Apollo Endosurgery (NASDAQ:APEN) reported its Q3 earnings results on Monday, November 1, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Accesswire
Neutral
Apollo Endosurgery, Inc. Reports 28% Revenue Growth in Third Quarter Conference Call and Webcast to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m.
2021-11-01 16:01

AUSTIN, TX / ACCESSWIRE / November 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2021 and recent corporate highlights. Third Quarter 2021 Selected Financial Results Total revenue of $16.4 million, an increase of 28% compared to the third quarter of 2020 Endoscopic Suturing System (ESS) revenue increased 34% and Intragastric Balloon (IGB) revenue increased 21% compared to the third quarter of 2020 Gross margin of 56% Pro forma cash of $98.3 million, including net proceeds from October 2021 follow-on offering Recent Corporate Highlights Announced that investigators of the Multi-Center ESG Randomized Interventional (MERIT) study reported data from the MERIT-Trial, which met its primary endpoints for safety and efficacy, with patients undergoing the Endoscopic Sleeve Gastroplasty (ESG) procedure achieving excess body weight loss

Accesswire
Neutral
Apollo Endosurgery Announces Publication of a Multicenter Study of Its X-Tack(R)Endoscopic HeliX Tacking System
2021-11-01 09:30

Study demonstrates high success rates, ease of use, and economic value in the treatment of GI defects AUSTIN, TX / ACCESSWIRE / November 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the publication of a multi-center study of the X-Tack®System in closing challenging gastrointestinal defects. Removal of gastrointestinal lesions is one of the most common procedures in endoscopy and may result in defects which can lead to perforation or bleeding if not closed properly.

Benzinga
Neutral
Apollo Endosurgery's Earnings Outlook
2021-10-29 10:42

Apollo Endosurgery (NASDAQ:APEN) is set to give its latest quarterly earnings report on Monday, 2021-11-01. Here's what investors need to know before the announcement.

Accesswire
Neutral
Apollo Endosurgery to Report Third Quarter Financial Results on November 1, 2021
2021-10-27 08:00

AUSTIN, TX / ACCESSWIRE / October 27, 2021 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2021 on Monday, November 1, 2021 after the market closes. In conjunction with the release, Apollo will host a live webcast audio call with slides at 3:30 p.m.

Accesswire
Neutral
Apollo Endosurgery Announces Positive MERIT-Trial Outcomes
2021-10-22 16:05

Trial Results Demonstrate ESG Procedure Offers Significant and Durable Weight Loss, with Improvements in Obesity-Related Health Conditions MERIT-Trial met its primary endpoints for safety and efficacy, with patients undergoing the Endoscopic Sleeve Gastroplasty (ESG) procedure achieving excess body weight loss of 49.2% at 12 months and a serious adverse event rate of 2% Patients undergoing ESG also had clinically significant reductions in diabetes, hypertension and metabolic syndrome at 12 months AUSTIN, TX / ACCESSWIRE / October 22, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that study investigators of the Multi-Center ESG Randomized Interventional Trial (MERIT) presented positive outcomes. Dr. Barham Abu Dayyeh, Professor of Medicine and Director of Advanced Endoscopy at the Mayo Clinic, presented the data at the International Federation for the Surgery of Obesity and Metabolic

Accesswire
Neutral
Apollo Endosurgery Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares
2021-10-15 16:05

AUSTIN, TX / ACCESSWIRE / October 15, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the closing of its previously announced underwritten public offering. Apollo sold 9,660,000 shares of its common stock, including 1,260,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a public offering price of $7.75 per share for gross proceeds of approximately $75 million, before deducting underwriting discounts and commissions and offering expenses.

Loading more news...